Upgrade to SI Premium - Free Trial

Travere Therapeutics (TVTX)

52.58 +0.28 (0.54%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (10/22/26)

Latest Headlines

Form 4 Travere Therapeutics, For: Oct 15 Filed by: Dube Eric M October 19, 2026 4:05 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Dube Eric M October 15, 2026 4:41 PM - SEC Filing Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 12, 2026 5:00 PM - BizWire Travere to present Filspari kidney disease data at ASN 2026 October 2, 2026 10:00 AM - StreetInsider Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026 October 2, 2026 10:00 AM - BizWire Travere Therapeutics (TVTX) PT Raised to $89 at Guggenheim September 24, 2026 6:11 AM - StreetInsider Travere gets patent allowance for Filspari use in kidney disease September 23, 2026 7:00 AM - StreetInsider Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental September 23, 2026 7:00 AM - BizWire Form 8-K Travere Therapeutics, For: Sep 21 September 21, 2026 4:11 PM - SEC Filing Travere Therapeutics names new CEO effective December 2026 September 21, 2026 4:05 PM - StreetInsider Travere Therapeutics Announces Planned Chief Executive Officer Transition September 21, 2026 4:05 PM - BizWire Form 4 Travere Therapeutics, For: Sep 15 Filed by: ROTE WILLIAM E. September 17, 2026 9:36 PM - SEC Filing Form 4 Travere Therapeutics, For: Sep 15 Filed by: Heerma Peter September 17, 2026 9:35 PM - SEC Filing Form 4 Travere Therapeutics, For: Sep 15 Filed by: Inrig Jula September 17, 2026 9:34 PM - SEC Filing Form 4 Travere Therapeutics, For: Sep 15 Filed by: REED ELIZABETH E September 17, 2026 9:33 PM - SEC Filing Form 4 Travere Therapeutics, For: Sep 15 Filed by: Dube Eric M September 17, 2026 9:32 PM - SEC Filing Form 4 Travere Therapeutics, For: Sep 15 Filed by: Cline Christopher R. September 17, 2026 9:30 PM - SEC Filing Form 4 Travere Therapeutics, For: Sep 15 Filed by: Calvin Sandra September 17, 2026 9:29 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Dube Eric M September 17, 2026 4:35 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Heerma Peter September 17, 2026 4:30 PM - SEC Filing Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum September 17, 2026 4:30 PM - BizWire Form 144 Travere Therapeutics, Filed by: ROTE WILLIAM E. September 16, 2026 4:33 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Heerma Peter September 16, 2026 4:33 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Dube Eric M September 16, 2026 4:31 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Calvin Sandra September 15, 2026 4:45 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Cline Christopher R. September 15, 2026 4:44 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: REED ELIZABETH E September 15, 2026 4:44 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Dube Eric M September 15, 2026 4:43 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Heerma Peter September 15, 2026 4:42 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: ROTE WILLIAM E. September 15, 2026 4:35 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Inrig Jula September 15, 2026 4:24 PM - SEC Filing Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 11, 2026 5:00 PM - BizWire Form 4 Travere Therapeutics, For: Sep 10 Filed by: Meckler Jeffrey A September 11, 2026 4:06 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: Meckler Jeffrey A September 10, 2026 4:38 PM - SEC Filing Form 4 Travere Therapeutics, For: Aug 17 Filed by: LYONS GARY A August 19, 2026 4:05 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: LYONS GARY A August 18, 2026 4:24 PM - SEC Filing Form 144 Travere Therapeutics, Filed by: LYONS GARY A August 17, 2026 4:32 PM - SEC Filing Travere Therapeutics (TVTX) PT Raised to $68 at Piper Sandler August 17, 2026 7:44 AM - StreetInsider Form SCHEDULE 13G/A Travere Therapeutics, Filed by: ARMISTICE CAPITAL, LLC August 14, 2026 10:29 AM - SEC Filing Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 12, 2026 5:00 PM - BizWire Form SCHEDULE 13G Travere Therapeutics, Filed by: BANK OF AMERICA CORP /DE/ August 12, 2026 1:29 PM - SEC Filing Form SCHEDULE 13G Travere Therapeutics, Filed by: STATE STREET CORP August 7, 2026 11:03 AM - SEC Filing Form SCHEDULE 13G/A Travere Therapeutics, Filed by: FMR LLC August 6, 2026 10:44 AM - SEC Filing Travere Therapeutics (TVTX) PT Raised to $70 at Canaccord August 6, 2026 6:42 AM - StreetInsider Travere Therapeutics (TVTX) PT Raised to $80 at Wells Fargo August 6, 2026 6:38 AM - StreetInsider Travere Therapeutics to Participate at Upcoming Investor Conferences August 5, 2026 4:30 PM - BizWire Travere Therapeutics (TVTX) PT Raised to $75 at Wedbush August 5, 2026 9:55 AM - StreetInsider Travere Therapeutics (TVTX) PT Raised to $62 at Stifel August 5, 2026 8:25 AM - StreetInsider Travere Therapeutics (TVTX) PT Raised to $75 at TD Cowen August 5, 2026 8:15 AM - StreetInsider Travere Therapeutics (TVTX) PT Raised to $85 at Citi August 5, 2026 4:56 AM - StreetInsider Travere Therapeutics (TVTX) Misses Q2 EPS by 2c August 5, 2026 12:47 AM - StreetInsider Form 10-Q Travere Therapeutics, For: Jun 30 August 4, 2026 4:46 PM - SEC Filing Form 8-K Travere Therapeutics, For: Aug 04 August 4, 2026 4:06 PM - SEC Filing Travere Therapeutics Reports Second Quarter 2026 Financial Results August 4, 2026 4:01 PM - BizWire Travere Therapeutics (TVTX) PT Raised to $62 at Canaccord July 30, 2026 7:21 AM - StreetInsider Travere Therapeutics to Report Second Quarter 2026 Financial Results July 28, 2026 4:30 PM - BizWire Full Article List